HUTCHMED (China) Ltd
00013
Company Profile
Business description
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
Contact
2 Queen's Road Central
48th Floor, Cheung Kong Center
Hong Kong
HKGT: +852 2121 8200
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
1,796
Stocks News & Analysis
stocks
Chart of the Week: Recent selloffs in this ASX sector opens doors to opportunity
Ongoing rate hikes have investors spooked.
stocks
ASX dividend champions: Stocks, ETFs and LICs
Mark and Shani run through lessons for ASX stocks, ETFs and LICs that have delivered over the past decade.
stocks
SpaceX’s IPO filing: Big spending, big losses
The first public financials from Elon Musk’s company highlight Starlink’s revenue power and increased spending on AI.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,856.30 | 6.00 | 0.07% |
| CAC 40 | 8,117.42 | 135.66 | 1.70% |
| DAX 40 | 24,737.24 | 336.59 | 1.38% |
| Dow JONES (US) | 50,009.35 | 645.47 | 1.31% |
| FTSE 100 | 10,432.34 | 101.79 | 0.99% |
| HKSE | 25,620.58 | 30.54 | -0.12% |
| NASDAQ | 26,270.36 | 399.65 | 1.54% |
| Nikkei 225 | 61,945.34 | 2,140.93 | 3.58% |
| NZX 50 Index | 12,803.41 | 42.38 | 0.33% |
| S&P 500 | 7,432.97 | 79.36 | 1.08% |
| S&P/ASX 200 | 8,635.50 | 7.50 | 0.09% |
| SSE Composite Index | 4,174.79 | 12.61 | 0.30% |